By Professor Elgene Lim

Conference Abstracts

Freelander A; laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2023, 'Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models', in Cancer Research, American Association for Cancer Research (AACR), Vol. 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-08-16

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; Ma CX; García-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 1021 - 1021, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1021

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS1121 - TPS1121, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps1121

Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 82, http://dx.doi.org/10.1158/1538-7445.SABCS21-PD2-02

Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E, 2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong V; De Boer R; Baron-Hay S; Blum R; Forster B; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott LW; Nottage M; Tafreshi A; Tsoi D; Uccelini A; Gibbs P; Lok SW, 2021, 'Patient-reported outcomes of medicine access programmes: A sub-study of KARMA (Kisqali Access Registry for Metastatic Breast Cancer in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 175 - 176, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wu SZ; Roden D; Al Eryani G; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'An integrated multi-omic cellular atlas of human breast cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263502037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore HM; Boni V; Bellet M; De Las Heras BB; Cortes MG; Oakman C; Schmid P; Trinh XB; Wheatley D; Jhaveri KL; Kabos P; Lim E; Velu T; Metcalfe C; Gates MR; Chang C-W; Bond J; Goldstein LD; Lauchle JO; Bardia A, 2021, 'Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.577

Yap Y-S; Kim S-B; Chiu JWY; Lim E; Broom R; Liu Z; Sagara Y; Chao T-Y; Sherwood S; McNaughton RE; Wei RJ; Toi M, 2021, 'Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S41 - S42, presented at ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 05 May 2021 - 08 May 2021, http://dx.doi.org/10.1016/j.annonc.2021.03.062

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner M; Brufsky AM; Overmoyer B, 2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S66 - S66, presented at ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 05 May 2021 - 08 May 2021, http://dx.doi.org/10.1016/j.annonc.2021.03.114

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2021, 'EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700638&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2020, 'Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700249&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology, Chicago, presented at American Society of Clinical Oncology, Chicago, 29 May 2020 - 31 May 2020

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Lok SW; Baron-Hay S; Lim E; Blum R; Boyle F; Clarke K; Cuff K; Green M; Malik L; Mok K; Murray N; Nott L; Nottage M; Tafreshi A; Tsoi D; Yeo B; Gibbs P; De Boer R, 2019, 'A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-OT2-02-01

Jhaveri K; Winer EP; Lim E; Fidalgo JA; Bellet M; Mayer IA; Boni V; Patel JM; Bardia A; Garcia JM; Kabos P; Gates M; Chen Y-C; Fredrickson J; Wang X; Friedman LS; Spoerke J; Gendreau S; Metcalfe C; Liu L; Chang C-W; Monemi S; Gonzalez M; McCurry U; Milan S; Humke EW; Loi S, 2019, 'A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD7-05

Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Hartman DG; Gable JC; Price GL; Hossain A; Gainford MC; Ezquerra MB, 2019, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P5-14-05

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034

Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Abstract P6-20-04: Activation of AR inhibits growth of endocrine-resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 79, pp. p6-20-04-p6-20-04, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-20-04

Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-21-05

Swarbrick A; Wu SZ; Roden D; Al-Eryani G; O'Toole S; Lim E, 2018, 'Landscape of the breast tumour microenvironment at single-cell resolution', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-GS1-01

Metzger O; Mandrekar S; Loibl S; Mundhenke C; Seiler S; Valagussa P; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller K; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Delalogue S; Vaz-Luis I; Dockter T; Lanzillotti J; Ciruelos E; DeMichele AM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+antiHER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-OT3-02-07

Swarbrick A; Cazet A; Hui M; O'Toole S; Lim E; Martin M, 2018, 'Small molecule inhibition of smoothened in triple negative breast cancer-associated fibroblasts depletes cancer stem cells and sensitizes to cytotoxic chemotherapy in mice and humans', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P5-07-03

Carson E; Segara D; Parker A; O'Toole S; Coates A; Mann B; Lindeman G; Tilley W; Lim E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-OT1-01-03

Lim E; Carson E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Asia-Pacific Journal of Clinical Oncology, Wiley, Perth Convention and Exhibition Centre, Perth, Western Australia, Vol. 14, pp. 194 - 195, presented at COSA's 45th Annual Scientific Meeting, Perth Convention and Exhibition Centre, Perth, Western Australia, 13 November 2018 - 15 November 2018, http://dx.doi.org/10.1111/ajco.13089

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2+therapy plus endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, Vol. 29, pp. 121 - 121, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277300360&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii121, http://dx.doi.org/10.1093/annonc/mdy272.357

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425489401175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Anderson RL; Swarbrick A; Johnstone R; Chua B; Gill A; Saunders C; Lakhani S; Lim E; Loi S; O'Toole SA; Khanna KK; Devereux L; Harvey K; Reed AM, 2017, 'Brocade: The National Breast Cancer Foundation Repository of Primary Tumours and Metastases from Breast Cancer Patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 110 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596

Seah D; Robinson D; Churilov L; Lin NU; Lim E, 2016, 'ATTITUDES OF PATIENTS WITH METASTATIC CANCER TOWARD RESEARCH BIOPSIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 12, pp. 107 - 108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E, 2016, 'TRANSLATING MOLECULAR INSIGHTS IN ESTROGEN RECEPTOR SIGNALING INTO CLINICAL TRIALS IN BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 12, pp. 82 - 83, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900058&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cao SA; Lim E; Brown M; Bailey ST, 2014, 'Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 75, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-05-14

Chi D; He H; Yeung T; Jeselsohn R; Schnitt S; Garber J; Richardson A; Lim E; Brown M, 2013, 'Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases.', in Cancer Research, American Association for Cancer Research (AACR), Vol. 73, pp. 2313 - 2313, http://dx.doi.org/10.1158/1538-7445.am2013-2313

Johnson SF; Johnson N; Chi D; Primack B; D'Andrea AD; Lim E; Shapiro GI, 2013, 'The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, Vol. 73, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-1788

Back to profile page